172 related articles for article (PubMed ID: 30321546)
1. Physiologically Based Modeling of the Pharmacokinetics of "Catch-and-Release" Anti-Carcinoembryonic Antigen Monoclonal Antibodies in Colorectal Cancer Xenograft Mouse Models.
Polli JR; Engler FA; Balthasar JP
J Pharm Sci; 2019 Jan; 108(1):674-691. PubMed ID: 30321546
[TBL] [Abstract][Full Text] [Related]
2. "Catch-and-Release" Anti-Carcinoembryonic Antigen Monoclonal Antibody Leads to Greater Plasma and Tumor Exposure in a Mouse Model of Colorectal Cancer.
Engler FA; Polli JR; Li T; An B; Otteneder M; Qu J; Balthasar JP
J Pharmacol Exp Ther; 2018 Jul; 366(1):205-219. PubMed ID: 29735609
[TBL] [Abstract][Full Text] [Related]
3. Application of PBPK modeling to predict monoclonal antibody disposition in plasma and tissues in mouse models of human colorectal cancer.
Abuqayyas L; Balthasar JP
J Pharmacokinet Pharmacodyn; 2012 Dec; 39(6):683-710. PubMed ID: 23184417
[TBL] [Abstract][Full Text] [Related]
4. Cell Penetrating Peptides Conjugated to Anti-Carcinoembryonic Antigen "Catch-and-Release" Monoclonal Antibodies Alter Plasma and Tissue Pharmacokinetics in Colorectal Cancer Xenograft Mice.
Polli JR; Balthasar JP
Bioconjug Chem; 2022 Aug; 33(8):1456-1466. PubMed ID: 35867869
[TBL] [Abstract][Full Text] [Related]
5. Application of a catenary PBPK model to predict the disposition of "catch and release" anti-PCSK9 antibodies.
Glassman PM; Balthasar JP
Int J Pharm; 2016 May; 505(1-2):69-78. PubMed ID: 27041125
[TBL] [Abstract][Full Text] [Related]
6. Target mediated disposition of T84.66, a monoclonal anti-CEA antibody: application in the detection of colorectal cancer xenografts.
Urva SR; Balthasar JP
MAbs; 2010; 2(1):67-72. PubMed ID: 20081377
[TBL] [Abstract][Full Text] [Related]
7. Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody.
Urva SR; Yang VC; Balthasar JP
J Pharm Sci; 2010 Mar; 99(3):1582-600. PubMed ID: 19774657
[TBL] [Abstract][Full Text] [Related]
8. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
Shah DK; Betts AM
J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic mAb-mAb interaction: anti-VEGF mAb decreases the distribution of anti-CEA mAb into colorectal tumor xenografts.
Abuqayyas L; Balthasar JP
AAPS J; 2012 Sep; 14(3):445-55. PubMed ID: 22528507
[TBL] [Abstract][Full Text] [Related]
10. Impact of Different Selectivity between Soluble and Membrane-bound Forms of Carcinoembryonic Antigen (CEA) on the Target-mediated Disposition of Anti-CEA Monoclonal Antibodies.
Iwano J; Shinmi D; Masuda K; Murakami T; Enokizono J
Drug Metab Dispos; 2019 Nov; 47(11):1240-1246. PubMed ID: 31533926
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib Decreases Tumor Exposure to an Anti-carcinoembryonic Antigen Monoclonal Antibody in a Mouse Model of Colorectal Cancer.
Thomas VA; Balthasar JP
AAPS J; 2016 Jul; 18(4):923-32. PubMed ID: 27029796
[TBL] [Abstract][Full Text] [Related]
12. Dynamic Contrast-Enhanced Magnetic Resonance Imaging for the Prediction of Monoclonal Antibody Tumor Disposition.
Bordeau BM; Polli JR; Schweser F; Grimm HP; Richter WF; Balthasar JP
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054865
[TBL] [Abstract][Full Text] [Related]
13. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
Glassman PM; Balthasar JP
J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
[TBL] [Abstract][Full Text] [Related]
14. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice.
Sundaresan G; Yazaki PJ; Shively JE; Finn RD; Larson SM; Raubitschek AA; Williams LE; Chatziioannou AF; Gambhir SS; Wu AM
J Nucl Med; 2003 Dec; 44(12):1962-9. PubMed ID: 14660722
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of colorectal tumor targeting using a novel biparatopic monoclonal antibody against carcinoembryonic antigen in experimental radioimmunoguided surgery.
Kim JC; Roh SA; Koo KH; Ryu JH; Hong HK; Oh SJ; Ryu JS; Kim HJ; Bodmer WF
Int J Cancer; 2002 Feb; 97(4):542-7. PubMed ID: 11802220
[TBL] [Abstract][Full Text] [Related]
16. Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys.
Glassman PM; Chen Y; Balthasar JP
J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):527-40. PubMed ID: 26364301
[TBL] [Abstract][Full Text] [Related]
17. PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody.
Cai W; Olafsen T; Zhang X; Cao Q; Gambhir SS; Williams LE; Wu AM; Chen X
J Nucl Med; 2007 Feb; 48(2):304-10. PubMed ID: 17268029
[TBL] [Abstract][Full Text] [Related]
18. Combination of antibody targeting and PTD-mediated intracellular toxin delivery for colorectal cancer therapy.
Shin MC; Zhang J; Ah Min K; Lee K; Moon C; Balthasar JP; Yang VC
J Control Release; 2014 Nov; 194():197-210. PubMed ID: 25204286
[TBL] [Abstract][Full Text] [Related]
19. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
[TBL] [Abstract][Full Text] [Related]
20. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.
Behr TM; Sharkey RM; Juweid MI; Dunn RM; Ying Z; Zhang CH; Siegel JA; Gold DV; Goldenberg DM
Cancer Res; 1996 Apr; 56(8):1805-16. PubMed ID: 8620497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
